MA32968B1 - Composes quinazoline substitues - Google Patents

Composes quinazoline substitues

Info

Publication number
MA32968B1
MA32968B1 MA34018A MA34018A MA32968B1 MA 32968 B1 MA32968 B1 MA 32968B1 MA 34018 A MA34018 A MA 34018A MA 34018 A MA34018 A MA 34018A MA 32968 B1 MA32968 B1 MA 32968B1
Authority
MA
Morocco
Prior art keywords
methods
kinase
disorder
substituted quinazoline
compounds
Prior art date
Application number
MA34018A
Other languages
Arabic (ar)
English (en)
Inventor
Caroline Leriche
Eric Auclair
Roux Jacques Le
David N Middlemiss
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41735344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32968(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of MA32968B1 publication Critical patent/MA32968B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION PORTE SUR CERTAINS COMPOSÉS NOUVEAUX, SUR LEURS MÉTHODES DE PRODUCTION ET SUR DES MÉTHODES DE TRAITEMENT OU D'AMÉLIORATION D'UN TROUBLE À MÉDIATION PAR UNE KINASE. PLUS PARTICULIÈREMENT, CETTE INVENTION PORTE SUR DES COMPOSÉS QUINAZOLINE SUBSTITUÉS UTILES EN TANT QU'INHIBITEURS DE KINASE SÉLECTIFS, SUR DES MÉTHODES DE PRODUCTION DE TELS COMPOSÉS ET SUR DES MÉTHODES DE TRAITEMENT OU D'AMÉLIORATION D'UN TROUBLE ENTRAÎNÉ PAR UNE KINASE. EN PARTICULIER, LES MÉTHODES PORTENT SUR LE TRAITEMENT OU L'AMÉLIORATION D'UN TROUBLE ENTRAÎNÉ PAR UNE KINASE COMPRENANT LES MALADIES CARDIO-VASCULAIRES, LE DIABÈTE, LES TROUBLES LIÉS AU DIABÈTE, LES MALADIES INFLAMMATOIRES, LES TROUBLES IMMUNOLOGIQUES, LE CANCER ET LES MALADIES DES YEUX TELLES QUE LES RÉTINOPATHIES OU LA DÉGÉNÉRESCENCE MACULAIRE OU AUTRE MALADIE VITRÉO-RÉTINIENNE ET SIMILAIRE.
MA34018A 2008-12-29 2009-12-18 Composes quinazoline substitues MA32968B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08360043 2008-12-29
PCT/EP2009/067494 WO2010076238A1 (fr) 2008-12-29 2009-12-18 Composés quinazoline substitués

Publications (1)

Publication Number Publication Date
MA32968B1 true MA32968B1 (fr) 2012-01-02

Family

ID=41735344

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34018A MA32968B1 (fr) 2008-12-29 2009-12-18 Composes quinazoline substitues

Country Status (23)

Country Link
US (1) US8389530B2 (fr)
EP (1) EP2381943A1 (fr)
JP (1) JP2012514020A (fr)
KR (1) KR20110120878A (fr)
CN (1) CN102333533A (fr)
AU (1) AU2009334869A1 (fr)
BR (1) BRPI0924067A2 (fr)
CA (1) CA2748319A1 (fr)
CO (1) CO6390105A2 (fr)
CR (1) CR20110368A (fr)
DO (1) DOP2011000209A (fr)
EA (1) EA019110B1 (fr)
EC (1) ECSP11011204A (fr)
IL (1) IL213742A0 (fr)
MA (1) MA32968B1 (fr)
MX (1) MX2011007064A (fr)
NI (1) NI201100134A (fr)
NZ (1) NZ593949A (fr)
PE (1) PE20120424A1 (fr)
SG (1) SG172415A1 (fr)
TN (1) TN2011000319A1 (fr)
WO (1) WO2010076238A1 (fr)
ZA (1) ZA201104777B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201204723A (en) 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
LT2872491T (lt) 2012-07-11 2021-08-25 Blueprint Medicines Corporation Fibroblasto augimo faktoriaus receptoriaus inhibitoriai
JP6458023B2 (ja) 2013-10-25 2019-01-23 ブループリント メディシンズ コーポレイション 繊維芽細胞成長因子受容体の阻害剤
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
KR101715448B1 (ko) * 2014-07-16 2017-03-20 주식회사 큐리언트 염증성 질환 치료용 화합물
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
JP6356919B2 (ja) 2014-12-24 2018-07-11 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のためのイソキノリン化合物
NZ733135A (en) 2014-12-24 2018-06-29 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
CN112239459B (zh) * 2019-07-19 2021-11-26 中国科学院上海药物研究所 稠环嘧啶氨基化合物、其制备方法、药物组合物及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1235815A1 (fr) * 1999-11-22 2002-09-04 Warner-Lambert Company Quinazolines et leur utilisation dans l'inhibition des enzymes kinase dependant de la cycline
WO2004065378A1 (fr) 2003-01-17 2004-08-05 Warner-Lambert Company Llc Heterocycles 2-aminopyridines substitues utilises comme inhibiteurs de la proliferation cellulaire
CA2542329A1 (fr) 2003-10-16 2005-04-28 Chiron Corporation Quinoxalines, quinolines, isoquinolines et quinazolines 2,6-bisubstituees servant d'inhibiteurs a la kinase raf pour le traitement du cancer
CA2567574C (fr) 2004-04-08 2013-01-08 Targegen, Inc. Inhibiteurs benzotriazine de kinases
CA2578283A1 (fr) 2004-08-25 2006-03-02 Targegen, Inc. Composes heterocycliques et methodes d'utilisation
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
AU2006227628A1 (en) 2005-03-16 2006-09-28 Targegen, Inc. Pyrimidine compounds and methods of use
US7906522B2 (en) * 2005-04-28 2011-03-15 Kyowa Hakko Kirin Co., Ltd 2-aminoquinazoline derivatives
WO2006133411A1 (fr) 2005-06-08 2006-12-14 Targegen, Inc. Methodes et preparations pour le traitement de troubles oculaires
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
EA200900819A1 (ru) * 2006-12-22 2010-02-26 Новартис Аг Хиназолины для ингибирования pdk1

Also Published As

Publication number Publication date
ZA201104777B (en) 2012-03-28
MX2011007064A (es) 2012-01-20
BRPI0924067A2 (pt) 2016-01-26
CR20110368A (es) 2011-12-02
WO2010076238A1 (fr) 2010-07-08
DOP2011000209A (es) 2011-09-30
EP2381943A1 (fr) 2011-11-02
SG172415A1 (en) 2011-07-28
CA2748319A1 (fr) 2010-07-08
KR20110120878A (ko) 2011-11-04
JP2012514020A (ja) 2012-06-21
PE20120424A1 (es) 2012-05-04
EA019110B1 (ru) 2014-01-30
AU2009334869A1 (en) 2011-07-14
TN2011000319A1 (en) 2012-12-17
AU2009334869A2 (en) 2011-09-29
EA201101012A1 (ru) 2012-01-30
US20120004210A1 (en) 2012-01-05
US8389530B2 (en) 2013-03-05
CN102333533A (zh) 2012-01-25
NZ593949A (en) 2013-08-30
CO6390105A2 (es) 2012-02-29
IL213742A0 (en) 2011-07-31
NI201100134A (es) 2012-03-06
ECSP11011204A (es) 2011-10-31

Similar Documents

Publication Publication Date Title
MA32968B1 (fr) Composes quinazoline substitues
FR21C1031I2 (fr) Derives de la n4-phenyl-quinazoline-4-amine et composes similaires en tant que inhibiteurs de la kinase tyrosine erbb type i pour le traitement de maladies hyperproliferatives
CY1122238T1 (el) Νεα 1-ναφθυλ-3-αζαδικυκλο[3.1.0]εξανia: παρασκευη και χρηση για τη θεραπεια νευροψυχιατρικων διαταραχων
ATE528302T1 (de) 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind
MA30337B1 (fr) Anticorps
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA30557B1 (fr) Composés de pyrrolopyrimidine et leurs utilisations.
MA30772B1 (fr) Composes et compositions utilises en tant qu'inhibiteurs de proteine kinase
TW200630356A (en) Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole
MA31167B1 (fr) Inhibiteurs de l'activite de akt
WO2006091801A3 (fr) Procedes pour traiter une angiogenese oculaire, un oedeme retinien, une ischemie retinienne et une retinopathie diabetique en utilisant des inhibiteurs de rtk selectifs
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
TN2010000130A1 (fr) Derives de quinazolinedione, leur preparation et leurs applications therapeutiques
BRPI0509391A (pt) piridonas substituìdos como inibidores de poli(adp-ribose) polimerase (parp)
MA33716B1 (fr) Mutants de fgf21 et leurs utilisations
MA33534B1 (fr) Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine
MX2009008787A (es) Moduladores 2-aminopirimidina del receptor de histamina h4.
MA33975B1 (fr) Composés et méthodes de modulation des kinases et leurs indications d'emploi
MX2010003325A (es) Anticuepos novedosos.
MA33926B1 (fr) Aminopyrimidines en tant qu'inhibiteurs de la syk
TW200734327A (en) Aminopyrimidines useful as kinase inhibitors
WO2005115145A3 (fr) Inhibiteurs de quinazoline et quinoline kinase a substitution quinone
MA47392A1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
NO20090268L (no) Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor